BioTuesdays

Tag - Ed Arce

Acurx-Pharma-Logo
Markets

HCW starts Acurx Pharma at buy; PT $14

H.C. Wainwright launched coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $14 price target. The stock closed at $3.83 on Dec. 16. Acurx is a clinical stage biopharmaceutical company focused on...

December 19, 2022
Enanta Logo
Markets

HCW starts Enanta Pharma at buy; PT $56

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...

December 9, 2022
Vera-Therapeutics
Markets

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

May 2, 2022
89bio
Markets

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

December 20, 2021
Pliant Therapeutics
Markets

HCW starts Pliant Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2. Pliant is a clinical-stage biopharmaceutical company focused on the...

November 3, 2021
Assembly Biosciences
Markets

HCW starts Assembly Biosciences at neutral; PT $3.50

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10. Assembly is focused on developing treatments for chronic...

September 13, 2021
Axcella Logo
Markets

HCW starts Axcella Health at buy; PT $14

H.C. Wainwright initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $14 price target. The stock closed at $3.97 on July 2. Axcella Health is a clinical-stage biotechnology company pioneering a new...

July 6, 2021
Metacrine
Markets

HCW starts Metacrine at buy; PT $15

H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...

June 14, 2021
Arbutus Biopharma Logo
Markets

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

December 17, 2020